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To investigate TRAIL resistance mechanisms in hepatocellular carcinoma (HCC), we isolated a stable
TRAIL-resistant sub-population of the HCC cell line LH86, designated LH86-TR. Differential activation
of AKT was not responsible for acquisition of TRAIL resistance. Cells with both congenital and
acquired resistance to TRAIL exhibited increased Msi1 expression, which conferred TRAIL resistance
by activating ERK. Forced expression of Msi1 decreased the sensitivity of HCC cells to TRAIL both
in vitro and in vivo. Conversely, shRNA-mediated depletion of Msi1 enhanced TRAIL efﬁcacy.
SiRNA-mediated depletion of ERK overcame TRAIL resistance. Hence, we conclude that Msi1 is a
mediator of TRAIL resistance in HCC cells.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most common can-
cer and one of the leading causes of cancer-related death world-
wide [1]. Existing treatment modalities such as surgery,
radiofrequency ablation and chemotherapy have demonstrated
limited therapeutic efﬁcacy. Developing new cancer therapeutic
strategies is particularly important in human HCC. TRAIL (tumor
necrosis factor-related apoptosis-inducing ligand) displays potent
anticancer effects in a wide range of cancers resistant to conven-
tional therapy without apparent toxic side effects to normal cells
[2]. Binding of homotrimeric TRAIL to DR4 and DR5 induces
oligomerization of the receptors and promotes formation of the
death inducing signaling complex (DISC), resulting in activation
of the initiator caspase-8. In type I cells, death receptor-initiated
caspase-8 activation generates a signal strong enough to activate
downstream effector caspase-3 that triggers execution of apopto-
sis. In contrast, in type II cells, the magnitude of caspase-8activation is not sufﬁcient to directly activate caspase-3. Active
caspase-8 cleaves Bid, which induces activation of Bax, followed
by permeabilization of mitochondria. Pro-apoptotic proteins such
as cytochrome c, Smac and DIABLO are released from mitochon-
dria, activating caspase-9 and caspase-3 [3]. Several TRAIL-based
novel drugs targeting its receptors are in the preclinical or clinical
development [4]. Nevertheless, resistance to TRAIL-induced apop-
tosis in cancer cells is one impediment to the use of TRAIL-based
agents as antitumor drugs. Though many cancer cells are sensitive
to TRAIL-induced apoptosis congenitally, they can acquire TRAIL
resistance after long-time treatment by TRAIL.
Msi1 is a highly conserved RNA-binding protein that serves as a
stem cell marker in central nervous system. In neural stem cells,
Msi1 activates Notch signal and regulates neural stem cell self-re-
new [5]. In a medulloblastoma cell line Daoy, a subset of cell pro-
liferation, differentiation and survival genes belong to Notch,
Hedgehog and Wnt pathway are differently expressed after Msi1
knockdown [6]. Msi1 increases the growth and survival of many
glioma cell lines by promoting the activations of both Notch and
PI3K/AKT signaling [7]. ERK phosphorylation is increased in Msi1
overexpressing COMMA cells, associated with increasing PLF1
secretion and reduction of DKK3, promoting proliferation of
COMMA cells [8]. These ﬁndings suggest that Msi1 plays a pivotal
role in stem cell maintenance, nervous system development, and
tumorigenesis. The relationship between Msi1 functions and HCC
progresses is also studied recently. Msi1 is elevated in the selected
Fig. 1. Generation of TRAIL-resistant LH86-TR liver cancer cells. (A and B) TRAIL-dependent loss of viable cells, measured by the MTT assay. The data represent the mean and
standard deviation of experiments performed in triplicate. (C) Apoptosis was conﬁrmed by Annexin-V/PI staining following exposure to TRAIL for 3 h. (D) Immunoblots of
PARP showed the full length 116-and 89-kDa apoptosis-related cleaved fragments in the parental LH86 exposed to TRAIL, conﬁrming apoptotic cell death induced by TRAIL.
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invasion with activated EMT process [9]. Msi1 modulates prolif-
eration of HCC cells by inhibiting APC and DKK1 mRNA translation
[10]. Whether Msi1 regulates TRAIL sensitivity of HCC cells is still
unexplored.
Here we selected a HCC cell line LH86-TR, acquired resistance to
TRAIL, from a TRAIL-sensitive cell line LH86. Various oncogenes
and tumor suppressor genes tested in these two cell lines did not
express differently. Interestingly, p-AKT was decreased in LH86-
TR cells compared to LH86. Inhibition of AKT only marginally
improved TRAIL-induced apoptosis in acquired resistant HCC cells.
By comparing the expression of the stem cell markers between
LH86 and LH86-TR cells, we found that Msi1 expression was
increased in TRAIL-resistant cells. We also found that Msi1 con-
ferred TRAIL resistance by activating ERK. Inhibition of ERK could
sensitize HCC cells to TRAIL.2. Materials and methods
2.1. Cell lines
Human HCC cell lines Huh7, LH86, HLCZ01 were grown in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) with 10% fetal
bovine serum at 37 C in 5% CO2 [11].
2.2. Generation of TRAIL-resistant cells
We established a TRAIL-resistant cell line by exposing LH86
cells to increasing concentrations of TRAIL (from 5 ng/ml to
50 ng/ml). After 3 months selection, a TRAIL-resistant LH86-TR cell
line, able to grow in the presence of 50 ng/ml TRAIL, was isolated.
LH86-TR cells were maintained in DMEM in 10% fetal bovine serum
with continuous exposure to 10 ng/ml TRAIL.2.3. Reagents and antibodies
Mouse anti-caspase-9, anti-caspase-3, anti-Bax, anti-AKT, anti-
pAKT(473) and anti-PARP antibodies were purchased from Cell
Signaling Technology. Mouse anti-b-actin, anti-Bcl-xL and anti-
FLAG monoclonal antibodies were from Sigma. Anti-Msi1 antibody
was from Abcam. The antibodies anti-Bid, anti-PTEN, anti-K-RAS,
anti-p38, anti-ERK1 and p-ERK1/2 were obtained from Sangon.
Anti-pSTAT3(705) and anti-NOXA antibodies were from SANTA
CRUZ. Anti-caspase-8 and anti MCL-1 antibodies were from
Boster. The Annexin V-FITC apoptosis detection kit and TRAIL were
purchased from Merck Millipore and R&D Systems respectively.
2.4. Overexpression and knock down experiments
pENTER-Msi1 with C terminal Flag and His tag plasmid was pur-
chased from Vigene. The oligonucleotides encode 19-mer sequence
speciﬁc to the Msi1 mRNA were incorporated into the pSilencer-
neo plasmid (Ambion). The sequences of Msi1 shRNAs targeting
two regions of Msi1 were 50-AATCGTTCGAGTCACCATCTT-30 and
50-AATAACTCCGGCTGGCGTA GG-30. The siRNA sequence for ERK1
was 50-TTAGGTAGGTCATCCAGCT-30. All constructs were con-
ﬁrmed, and transfected into cells using Lipofectamine 2000
reagents (Invitrogen).
2.5. Western blot analysis
Cell lysates were prepared on ice, and protein concentrations
were determined using the BCA assay (Dingguo). Cell lysates were
separated on SDS–page gel and transfected to PVDF membrane
(Bio-Rad). Proteins were detected with the appropriate primary
antibody, horseradish peroxidase-linked secondary antibodies,
and visualized by chemiluminescence with the West Pico system
(Thermo).
Fig. 2. Differential regulation of pro-survival signals is not responsible for the acquisition of TRAIL resistance in LH86-TR. (A and B) LH86-TR and parental LH86 cells were
treated by TRAIL. Bid, cleavage form of caspase-9, cleavage form of caspase-3 and Noxa were determined by Western blot assay. (C and D) Parental LH86 and TRAIL-resistant
LH86-TR was treated with TRAIL and modulation of pro-survival and apoptotic signaling was compared by Western blot analysis. (E) AKT inhibitor LY294002 (10 lM) failed
to overcome resistance to TRAIL as determined by Western blot of PARP, caspase-9 and caspase-3 cleavage. (F) TRAIL receptors DR4, DR5, DcR1, DcR2 mRNA levels in LH86
and LH86-TR cells were determined by real-time PCR. Error bars represent S.D. from triplicate experiments. (G) DR4 and DR5 proteins were analyzed by Western blot.
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Total cellular RNA was extracted using TRZIOL reagent accord-
ing to the manufacturer’s protocol. One microgram of cellular
RNA was reverse-transcribed in a total volume of 20 ll using the
one-step script RT kit (Invitrogen). The primers targeted DR4,
DR5, DcR1, DcR2 have been reported previously [11]. The primers
targeted Msi1, CD133, SOX2, Oct4 have been described [9]. The
internal control was GAPDH. Fold variations were calculated after
normalization to GAPDH.
2.7. Flow cytometry analysis
LH86 and LH86-TR cells were treated with TRAIL for the indicat-
ed hours. Apoptosis was determined by staining cells with annexin
V-FITC and propidium iodide according to the manufacturer’s pro-
tocol (Merck). Samples were analyzed by using the FACScan ﬂow
cytometer (Beckman).
2.8. In vivo assay
Animal studies were performed in accordance with protocols
approved by the Institutional Laboratory Animal Care and Use
Committee of Hunan University. Stable-Msi1 expressing LH86 cells
and stable-Msi1 knockdown LH86-TR cells were selected with
antibiotics for 2 weeks. Nude mice were inoculated subcutaneous-
ly with 5  106 tumor cells/mouse and the tumors were allowed togrow to about 100 mm3. TRAIL (10 mg/kg/day) or vehicle (PBS) was
administered by tail vein injection every 3 days. Tumors were mea-
sured using calipers and their volumes calculated using the follow-
ing standard formula: width2  length  0.52.
2.9. Statistical analysis
Statistical analyses were performed with the two-tailed
Student’s t-test, and error bars represent S.D. ⁄P < 0.05, ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001.
3. Results
3.1. Generation of stable TRAIL-resistant human liver cancer cells
The human HCC cell line LH86 was used as a model to investi-
gate the mechanism of acquired TRAIL resistance because these
cells are relatively susceptible to TRAIL-induced cytotoxicity [11].
We obtained TRAIL-resistant stable cells by subjecting LH86 cells
to repeated exposure to TRAIL. Exposure of LH86 cells to TRAIL
resulted in a dose- (Fig. 1A) and time-dependent (Fig. 1B) reduction
in cell viability. Residual surviving cells were propagated with peri-
odic exposure to TRAIL to yield a TRAIL-resistant stable cell line,
LH86-TR. As shown in Fig. 1A and B, less than 10% loss of viable
cells could be detected in LH86-TR cells after exposure to 50 ng/
ml TRAIL for 24 h, in contrast to 75% loss of viable cells observed
in LH86 cells. To determine the nature of cell death induced by
Fig. 3. Msi1 is elevated in TRAIL-resistant cells. HCC cell lines were treated with or without TRAL for 4 h. Total RNA was extracted to perform real-time PCR analysis of CD133,
Oct4, Nanog, Sox2 (A) and Msi1 (B). (C) Msi1 mRNA was detected in LH86, LH86-TR, HLCZ01 and Huh7 cells. Error bars represented S.D. from triplicate experiments. ⁄P < 0.05,
⁄⁄P < 0.01 verse control non-treated cells. (D) Msi1 protein was determined by Western blot analysis.
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stage of apoptosis with annexin-V staining and the caspase-depen-
dent cleavage of PARP. Annexin-V staining showed that TRAIL
induced 20% apoptotic cells in LH86 (Fig. 1C), whereas LH86-TR
cells were resistant to TRAIL (7%). The PARP and caspase-8 assay
support the ﬁndings (Fig. 1D).
3.2. Pro-survival and apoptosis signaling in TRAIL-sensitive (LH86)
versus TRAIL-resistant (LH86-TR) liver cancer cells
Our previous study have found that the intrinsic apoptotic path-
way was activated in the TRAIL sensitive LH86 cells after treatment
with TRAIL [11], so we investigated whether this signaling path-
way was intact in LH86-TR cells. As shown in Fig. 2A and B, treat-
ment with TRAIL induced the increase of Bid activity as well as
caspase-9 and caspase-3 cleavage in a dose-dependent manner in
both cells. However, both caspases (caspase-9 and caspase-3) and
Bid activity in LH86-TR cells were markedly lower than that of par-
ental cells. The induction of mitochondrial-dependent apoptotic
pathway protein NOXA was also increased in LH86 cells compared
to in LH86-TR cells. These results suggest that the intrinsic apop-
totic pathway is disrupted in LH86-TR cells.
Previous study has suggested that STAT3 activation status may
play an important role in mediating TRAIL resistance in HCC cells
[12]. In this regard, we examined phosphorylated STAT3 in both
LH86 and LH86-TR cells and found that p-STAT3 existed only in
IFN-a treated cells. TRAIL did not induce STAT3 phosphorylation
in these two cell lines (Fig. 2C). To gain further insight on the mole-
cular basis of TRAIL resistance, we analyzed the expression of sev-
eral other oncogenes and tumor suppressors following treatment
with various concentrations of TRAIL. The examined genes suchas BAX, p-PTEN, p-P38, k-RAS, Bcl-2 and Bcl-xl were not markedly
changed in both cells after treated by TRAIL, the anti-apoptotic
protein MCL-1 was elevated in LH86-TR cells (Fig. 2D). In contrast,
the phosphorylation level of AKT was decreased dependent on the
increasing TRAIL concentrations, the basal level of activated AKT in
LH86-TR cells were much lower than in parental LH86 cells. The
differential activation of AKT is not responsible for the acquisition
of TRAIL resistance, because speciﬁc inhibition of AKT by LY294002
only slightly improved TRAIL-induced apoptosis (Fig. 2E). We also
examined the expression level of TRAIL death receptors by using
real-time PCR and Western blot analysis. No differences in expres-
sion levels of both death receptors (DR4 and DR5) and decoy recep-
tors (DcR4 and DcR5) were observed between the parental LH86
and the resistant LH86-TR cells (Fig. 2F and G).
3.3. Stem cell marker Msi1 is elevated in TRAIL resistant liver cancer
cells
Cancer stem cells (CSCs) subpopulation will be enriched in
chemotherapeutic reagents selected drug-resistant cancer cells
[9,13–15]. Next, we investigated if cancer stem cell markers and
pluripotency factors increased in TRAIL-resistant cells. We ﬁrst
compared the expression of CD133 between LH86 and LH86-TR
cells with TRAIL treatment. CD133 expression level in LH86-TR
cells was lower than in LH86 cells. TRAIL induced a little decrease
of CD133 in both cells. The stem cell transcription factors including
Oct4, Nanog, and Sox2 stem cell transcription factors were lower in
LH86-TR cells than in parental cells (Fig. 3A). Interestingly, though
short time treatment with TRAIL reduced Msi1 expression in both
cells, there was an over 10-fold increase of Msi1 in LH86-TR cells
(Fig. 3B). To further conﬁrm that Msi1 was increased in TRAIL-
Fig. 4. Msi1 depletion restores TRAIL-responsiveness to TRAIL-resistant cells. LH86-TR (A), Huh7 cells (B) and HLCZ01 (C) cells were transiently transfected with indicated
shRNA for 48 h and subsequently stimulated with TRAIL at different concentrations. Representative Western blot of knockdown efﬁciency and active form of caspase-9 and
PARP were shown. (D) In LH86-Msi1 implanted nude mouse, TRAIL showed lower inhibition effects on tumor growth. Msi1 was overexpressed in LH86 cells (right panel). (E)
In LH86-TR-shMsi1 implanted nude mouse, TRAIL showed higher inhibition effects on tumor growth. Msi1 knockdown efﬁcacy in LH86-TR cells was shown in right panel.
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LH86 and resistant LH86-TR, Huh7, HLCZ01 cells. As shown in
Fig. 3C, Msi1 level was much higher in resistant cells than in sen-
sitive cells. The Western blot assay conﬁrmed the ﬁndings
(Fig. 3D). These data suggested that Msi1 may play an important
role in TRAIL resistance.
3.4. Msi1 mediates TRAIL sensitivity of HCC cells in vitro and in vivo
To evaluate the effect of Msi1 knockdown on TRAIL-induced
apoptosis in HCC cell lines, we used shRNA to silence Msi1 expres-
sion. ShRNA knockdown reduced Msi1 protein expression com-
pared to control shRNA-transfected cells (Fig. 4A–C). Inhibition of
Msi1 increased TRAIL-induced cleavage of PARP level as well as
caspase-9 activation in LH86-TR cells (Fig. 4A). Similarly, Huh7
and HLCZ01 cells cultured in the presence of TRAIL showed higher
PARP and caspase-9 activation in Msi1 knockdown cells compared
to control shRNA-transfected cells (Fig. 4B and C). These results
suggest that Msi1 inhibition sensitizes HCC cells to TRAIL through
intrinsic apoptotic pathway activation. To test whether Msi1 regu-
lates TARIL-induced apoptosis in vivo, we overexpressed Msi1 in
LH86 cells or silenced it in LH86-TR cells. After selected with
antibiotics for 2 weeks, stable-Msi1 expressing LH86 cells and
stable-Msi1 knockdown LH86-TR cells were obtained (Fig. 4D
and E). Then these cells were implanted into the immunodeﬁciencynude mice, respectively. TRAIL treatment was initiated when the
tumor size reached to about 100 mm3. In nude mice, TRAIL treat-
ment has little inhibition effect on tumor growth in Msi1 overex-
pressing LH86 cells compared with control groups (Fig. 4D).
Conversely, knockdown of Msi1 sensitized LH86-TR cells to TRAIL
treatment (Fig. 4E). All these data suggested that Msi1 mediates
TRAIL sensitivity of HCC cells in vitro and in vivo.
3.5. ERK signaling is involved in Msi1-mediated TRAIL resistance of
HCC cells
Previous studies show that Msi1 reduction leads to a decrease
in the AKT signaling activity in Daoy cells [7]. Though AKT activity
is decreased in the LH86-TR cells which acquired resistance to
TRAIL (Fig. 2E), we wonder if Msi1 knockdown could reduce AKT
activity in this cell line. As shown in Fig. 5A, AKT activity was com-
pletely inhibited by treated with LY294002 but not changed after
treatment with Msi1-targeted shRNA in this cell line.
Interestingly, we found that ERK activity and its downstream gene
MCL-1 were decreased in Msi1-targeted shRNA transfected cells
compared with control shRNA transfected cells. The basal level of
p-ERK was higher in LH86-TR cells than in LH86 cells (Fig. 5B).
To further conﬁrm this ﬁnding, LH86 cells were transfected with
full-length Msi1 cDNA construct and treated by TRAIL. pERK and
MCL-1 levels were increased in Msi1 overexpressing cells compare
Fig. 5. Msi1 regulates ERK activation. (A) Msi1 knockdown had no effects on AKT activation. (B) Inhibition of Msi1 decreased ERK activation and MCL-1 expression in LH86-TR
cells (up). The basal level of p-ERK was examined by Western blot assay (down). (C) Overexpression of Msi1 increased ERK activation and MCL-1 expression and inhibited
TRAIL-induced apoptosis in LH86 cells. Apoptosis was measured by PARP cleavage. (D) Knock down of ERK sensitizes LH86-TR cells to TRAIL through downregulation of
MCL-1. (E) A schematic diagram showing the proposed Msi1 signaling cascade that regulates the acquired resistance to TRAIL in HCC cells.
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er in Msi1 overexpressing cells than in control cells (Fig. 5C). To
investigate whether inhibition of ERK could enhance TRAIL-in-
duced apoptosis, we knock down ERK in LH86-TR cells by using
speciﬁc siRNA. As shown in Fig. 5D, ERK and MCL-1 were inhibited
and activating form of PARP was increased in ERK knockdown cells.
These results indicated that Msi1 inhibits TRAIL-induced apoptosis
by activating ERK and inhibition of ERK can sensitize TRAIL-resis-
tant cells to TRAIL.
4. Discussion
Drug resistance is a common phenomenon and a major obstacle
to most cancer therapies, including TRAIL-based therapy. Many
tumor cells display resistance to TRAIL and susceptible tumor cells
may acquire resistance mechanisms due to adaptive changes in
response to therapy and selection of survival phenotypes. Both
congenital and acquired TRAIL resistance mechanisms have been
reported in some cell lines. STAT3 are involved in cell proliferation
and survival and frequently activated. Sorafenib inhibits STAT3
activation and overcomes TRAIL resistance in pancreatic cancers
and liver cancers [12,16,17]. These results indicate that STAT3
are involved in primary TRAIL resistance in tumor cells, although
we did not observe the different activation level of STAT3 between
LH86 and LH86-TR cells. Our previous study showed that ISG12a
modulates TRAIL sensitivity and is regulated by miR-942. ISG12a
basal level was lower in TRAIL resistant cells (such as Huh7 and
HLCZ01) than in TRAIL sensitive cells (LH86) [11]. Increased c-
FLIP and Mcl-1 expression confers acquired resistance to TRAIL-in-
duced cytotoxicity in lung cancer cells [18]. In colon adenocarcino-
ma cells, cell surface galectin-3 confers resistance to TRAIL by
impeding trafﬁcking of death receptors [19]. The acquired TRAIL
resistance mechanism is controversial and rarely studied in HCC
cells.In the present study, we demonstrated that TRAIL-sensitive HCC
cell line LH86 became resistant to TRAIL-induced apoptosis after
prolonged treatments with TRAIL. The intrinsic apoptotic pathway
was not activated in resistant cells compared to in sensitive cells
after treatment with TRAIL. Though increased AKT activity con-
tributes to TRAIL resistance in lung and breast cancer cells
[18,20], we found decreased AKT activity in LH86-TR cells.
Suppressing AKT activity with LY294002 did not sensitize LH86-
TR cells to TRAIL-induced cytotoxicity. These ﬁndings suggested
that AKT may not play a functional role in acquired TRAIL resis-
tance in HCC cells.
It has been reported that Msi1 modulates cell proliferation and
apoptosis in various cancer cells [6,7,21]. In an in vivo study, Msi1
knock down inhibits tumor growth [22]. Msi1 regulates cell sur-
vival by activating Wnt signaling pathway in liver cancer cells
[10]. Msi1 is elevated in selected sorafenib resistant HCC cell lines.
Increased Msi1 expression is associated with enhanced cellular
migration and invasion [9]. In our study, we found that Msi1 was
the only increased pluripotency factor among others in LH86-TR.
Knock down of Msi1 with speciﬁc shRNA sensitized LH86-TR cells
to TRAIL-induced apoptosis. Overexpression of Msi1 blocked
TRAIL-induced apoptosis in LH86 cells. As a potential cancer stem
cell marker, CD133 confers drug resistance in cancer cells [23]. The
level of CD133 is lower in LH86-TR cells than in parental cells. It
would be possible that cancer stem cells are not enriched in
LH86-TR cells and are not the main reason for TRAIL resistance in
this cell line. Msi1 exerts their regulatory functions by binding
the 30untranslated region of mRNA of the target and inhibits its
expression [24]. Whether Msi1 regulates CD133 expression by
binding the mRNA of CD133 needs to be further studied.
Previous study demonstrated that breast cancer cells acquire
resistance to TRAIL through ERK activation [25]. ERK activation
inhibits the processing of caspase-8 and Bid, thereby turning off
the mitochondrial ampliﬁcation loop [26,27]. Previous studies
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vation [28–30]. In our study, we observed that activation of ERK
and protein level of MCL-1 decreased in Msi1 knockdown LH86-
TR cells whereas increased in Msi1 overexpressing LH86 cells.
Furthermore, inhibiting ERK activation with siRNA overcomes the
acquired TRAIL resistance of LH86-TR cells. These ﬁndings suggest
that combination ERK inhibitor or speciﬁc siRNA with TRAIL can
sensitize TRAIL-resistant cells to TRAIL-induced apoptosis through
downregulation of MCL-1. A genomic analysis of Msi1 downstream
targets found many cancer-related genes [24]. Whether these Msi1
targeted genes are associated with TRAIL sensitivity needs to
further studied. Several miRNAs have been found to affect Msi1
expression [31]. It would be interesting to investigate whether the-
se miRNAs are decreased in TRAIL-resistant cells and regulate
TRAIL sensitivity by modulating Msi1 expression. A recent study
showed that Msi1 can serve as a diagnostic marker and a potential
therapeutic target in lung cancer cells [32], whether it has a similar
role in HCC cells remain to be explored.
In summary, we found that Msi1 is elevated in TRAIL-resistant
cells and confers TRAIL resistance through ERK activation. The
upregulated MCL-1 after ERK activation may also contributes to
acquire resistance to TRAIL in HCC cells (Fig. 5E). The inverse cor-
relation of Msi1 expression level and TRAIL sensitivity indicated
that Msi1 can serve as a TRAIL response marker with important
implications in designing new therapeutics.Conﬂict of interest
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